Literature DB >> 10898359

Gamma surgery for hemangiopericytomas.

B R Payne1, D Prasad, M Steiner, L Steiner.   

Abstract

A retrospective analysis of a consecutive series of 12 patients with 15 intracranial hemangiopericytomas treated at the University of Virginia using Gamma surgery is presented. Clinical and radiographic follow up of 3 to 56 months is available for 10 patients with 12 tumors. There was one tumor present at the time of initial Gamma surgery in each patient. Two new tumors occurred in patients previously treated. Nine of the tumors decreased in volume and three remained stable. Four of the nine tumors that shrank later progressed at an average of 22 months after treatment. Of the tumors that decreased in volume and have not progressed, the response has been for an average of 11 months. The follow-up for two tumors that remained unchanged was 10 and 34 months (average 22 months). A third tumor was unchanged at 42 months but the patient died of new disease adjacent to the treated area in the anterior skull base. There were no complications and the quality of life following the procedure was maintained or improved in every case. Gamma surgery is effective in palliating the patients by decreasing tumor volume and delaying recurrence.

Entities:  

Mesh:

Year:  2000        PMID: 10898359     DOI: 10.1007/s007010050465

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  11 in total

1.  Management of intracranial meningeal hemangiopericytomas: outcome and experience.

Authors:  K N Fountas; E Kapsalaki; M Kassam; C H Feltes; V G Dimopoulos; J S Robinson; J R Smith
Journal:  Neurosurg Rev       Date:  2006-01-04       Impact factor: 3.042

2.  Hemangiopericytoma of thoracic spine: a rare bony tumor.

Authors:  Raj Kumar; Vivek Kumar Vaid; Vimal Kumar; Samir Kumar Kalra
Journal:  Childs Nerv Syst       Date:  2007-05-31       Impact factor: 1.475

3.  Central nervous system hemangiopericytoma with bone and lung metastases: a case report.

Authors:  Alessia Fabbri; Elisa Grifoni; Gabriele Ciuti; Roberto Fedi; Alberto Moggi Pignone
Journal:  Intern Emerg Med       Date:  2013-07-03       Impact factor: 3.397

4.  Gamma Knife stereotactic radiosurgery for intracranial hemangiopericytomas.

Authors:  Jin Wook Kim; Dong Gyu Kim; Hyun-Tai Chung; Sun Ha Paek; Yong Hwy Kim; Jung Ho Han; Chul-Kee Park; Chae-Yong Kim; Hee-Won Jung
Journal:  J Neurooncol       Date:  2010-01-19       Impact factor: 4.130

5.  Rapid shrinkage of remnant central neurocytoma after gamma knife radiosurgery: a case report.

Authors:  Mutsuya Hara; Masaru Aoyagi; Masaaki Yamamoto; Taketoshi Maehara; Yoshiaki Takada; Takeko Nojiri; Kikuo Ohno
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

6.  Single-fraction stereotactic radiosurgery of meningeal hemangiopericytomas.

Authors:  William R Copeland; Michael J Link; Scott L Stafford; Bruce E Pollock
Journal:  J Neurooncol       Date:  2014-07-09       Impact factor: 4.130

7.  Gamma knife stereotactic radiosurgery for intracranial hemangiopericytoma.

Authors:  Takahiko Tsugawa; Yoshimasa Mori; Tatsuya Kobayashi; Chisa Hashizume; Yuta Shibamoto; Toshihiko Wakabayashi
Journal:  J Radiosurg SBRT       Date:  2014

8.  Intracranial solitary fibrous tumor/hemangiopericytoma mimicking cystic meningioma: A case report and literature review.

Authors:  Tomonori Chikasue; Yusuke Uchiyama; Shuichi Tanoue; Satoru Komaki; Yasuo Sugita; Toshi Abe
Journal:  Radiol Case Rep       Date:  2021-04-30

9.  CyberKnife stereotactic radiosurgery for recurrent, metastatic, and residual hemangiopericytomas.

Authors:  Anand Veeravagu; Bowen Jiang; Chirag G Patil; Marco Lee; Scott G Soltys; Iris C Gibbs; Steven D Chang
Journal:  J Hematol Oncol       Date:  2011-06-06       Impact factor: 17.388

10.  Treatment of Residual, Recurrent, or Metastatic Intracranial Hemangiopericytomas With Stereotactic Radiotherapy Using CyberKnife.

Authors:  Lichao Huang; Jingmin Bai; Yanyang Zhang; Zhiqiang Cui; Zhizhong Zhang; Jiwei Li; Jinyuan Wang; Xinguang Yu; Zhipei Ling; Baolin Qu; Longsheng Pan
Journal:  Front Oncol       Date:  2021-03-03       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.